Bausch Health Companies Inc.

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:01 09/05/2024 am IST			5-day change	1st Jan Change
7.03 ^USD	-5.13%		-19.75%	-12.34%

03/05	RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	MT
02/05	Bausch Health Shares Fall Following Q1 Results	MT

Bausch Health Companies Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 22, 2024 at 05:35 pm IST

Bausch Health Companies Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 2,408 million compared to USD 2,193 million a year ago. Net loss was USD 39 million compared to USD 410 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 1.13 a year ago.
For the full year, revenue was USD 8,757 million compared to USD 8,124 million a year ago. Net loss was USD 592 million compared to USD 225 million a year ago. Basic loss per share from continuing operations was USD 1.62 compared to USD 0.62 a year ago.

Latest news about Bausch Health Companies Inc.

RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	03/05	MT
Bausch Health Shares Fall Following Q1 Results	02/05	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	02/05	MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	02/05	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	02/05	MT
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
North American Morning Briefing : Stock Futures -2-	02/05	DJ
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	02/05	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	01/05	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	01/05	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	01/05	MT
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	25/04	MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25/04	MT
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says	23/04	MT
RBC Previews Bausch Health's Q1, Trims Target to US$11	23/04	MT
RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating	23/04	MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	22/04	MT
Bausch Health's Issuer Credit Rating Upgraded by S&P	19/04	MT
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	12/04	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	12/04	MT
Bausch wins US appeal to block Alvogen generic of diarrhea drug	11/04	RE
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan	11/04	CI
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	09/04	RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	08/04	MT

Chart Bausch Health Companies Inc.

Duration

Period

More charts

Company Profile

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

14/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

7.41 USD

Average target price

9.786 USD

Spread / Average Target

+32.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAUSCH HEALTH COMPANIES INC.	-12.34%	2.72B
ELI LILLY AND COMPANY	+32.95%	700B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	330B
ABBVIE INC.	+3.54%	287B
ASTRAZENECA PLC	+15.70%	236B
NOVARTIS AG	+6.68%	202B
ROCHE HOLDING AG	-9.08%	197B
AMGEN INC.	+6.70%	161B
PFIZER, INC.	-1.81%	157B

Other Pharmaceuticals